Royalty Pharma 10-Q 7 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	1-May-15
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Registrant Name	REPROS THERAPEUTICS INC.
Entity Central Index Key	897075
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Trading Symbol	RPRX
Entity Common Stock, Shares Outstanding		24,276,173

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current Assets
Cash and cash equivalents	$37,875	$46,620
Prepaid expenses and other current assets	569	289
Total current assets	38,444	46,909
Fixed assets, net	22	32
Total assets	38,466	46,941
Current Liabilities
Accounts payable	1,159	2,090
Accrued expenses	793	834
Total current liabilities	1,952	2,924
Commitments & Contingencies (note 6)
Stockholders' Equity
Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding	0	0
Common Stock, $.001 par value, 75,000,000 shares authorized, 24,388,523 shares issued; 24,276,173 shares outstanding	24	24
Additional paid-in capital	319,459	318,437
Cost of treasury stock, 112,350 shares	-1,380	-1,380
Accumulated deficit	-281,589	-273,064
Total stockholders' equity	36,514	44,017
Total liabilities and stockholders' equity	$38,466	$46,941

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	75,000,000	75,000,000
Common Stock, shares issued	24,388,523	24,388,523
Common Stock, shares outstanding	24,276,173	24,276,173
Treasury stock, shares	112,350	112,350
Undesignated Preferred Stock [Member]
Preferred Stock, par value	$0.00	$0.00
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, issued	0	0
Preferred Stock, outstanding	0	0

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenues and other income
Interest income	$1	$2
Total revenues and other income	1	2
Expenses
Research and development	7,321	7,569
General and administrative	1,205	1,226
Total expenses	8,526	8,795
Net loss	($8,525)	($8,793)
Loss per share - basic and diluted	($0.35)	($0.38)
Shares used in loss per share calculation:
Basic	24,276	23,033
Diluted	24,276	23,033

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Deficit
In Thousands, except Share data
Beginning Balance at Dec. 31, 2013	$72,519	$23	$314,405	($1,380)	($240,529)
Beginning Balance (in shares) at Dec. 31, 2013		23,125,565		112,350
Stock based option compensation	920	0	920	0	0
Issuance of 69,197 shares of common stock for the cashless exercise of 91,664 stock options	0	0	0	0	0
Issuance of 69,197 shares of common stock for the cashless exercise of 91,664 stock options (in shares)		69,197		0
Exercise of stock options to purchase common stock stock for cash ($1.56 to $9.60 per share)	104	0	104	0	0
Exercise of stock options to purchase common stock stock for cash ($1.56 to $9.60 per share) (in shares)		15,000		0
Net loss	-8,793	0	0	0	-8,793
Ending Balance at Mar. 31, 2014	64,750	23	315,429	-1,380	-249,322
Ending Balance (in shares) at Mar. 31, 2014		23,209,762		112,350
Beginning Balance at Dec. 31, 2014	44,017	24	318,437	-1,380	-273,064
Beginning Balance (in shares) at Dec. 31, 2014		24,388,523		112,350
Stock based option compensation	1,022	0	1,022	0	0
Net loss	-8,525	0	0	0	-8,525
Ending Balance at Mar. 31, 2015	$36,514	$24	$319,459	($1,380)	($281,589)
Ending Balance (in shares) at Mar. 31, 2015		24,388,523		112,350

CONSOLIDATED_STATEMENTS_OF_STO1

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) (USD $)	3 Months Ended
	Mar. 31, 2014
Issuance of shares of common stock for the cashless exercise of stock options	69,197
Cashless Exercise Of Stock Options	91,664
Maximum [Member]
Exercise of stock option to purchase common stock for cash, share price	9.6
Minimum [Member]
Exercise of stock option to purchase common stock for cash, share price	1.56

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash Flows from Operating Activities
Net loss	($8,525)	($8,793)
Depreciation	10	11
Noncash stock-based compensation	1,022	920
(Increase) decrease in prepaid expenses and other current assets	-382	-393
Increase (decrease) in accounts payable and accrued expenses	-972	356
Net cash used in operating activities	-8,847	-7,899
Cash Flows from Investing Activities
Capital expenditures	0	0
Net cash used in investing activities	0	0
Cash Flows from Financing Activities
Exercise of stock options & warrants	0	104
Proceeds from a shareholder transaction	102	0
Net cash provided by financing activities	102	104
Net decrease in cash and cash equivalents	-8,745	-7,795
Cash and cash equivalents at beginning of period	46,620	75,807
Cash and cash equivalents at end of period	$37,875	$68,012

Organization_Operations_and_Li

Organization, Operations and Liquidity	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Operations and Liquidity	NOTE 1 — Organization, Operations and Liquidity
	Repros Therapeutics Inc. (the “Company,” “RPRX,” “Repros,” or “we,” “us” or “our”) was organized on August 20, 1987. We are a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.
	Our enclomiphene product candidate, formerly known as Androxal®, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. We expect to rename this product candidate in the near future. We are developing enclomiphene for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Men with secondary hypogonadism exhibit low testosterone levels due to under stimulated testes but they are generally fertile. Enclomiphene is designed to treat the underlying mechanism, insufficient stimulation of the testes by the pituitary, which causes secondary hypogonadism. The Company believes that secondary hypogonadism due to being overweight or obese is the single greatest cause of hypogonadism in general. On February 2, 2015, we announced that we electronically submitted our New Drug Application (“NDA”) to the Food and Drug Administration (“FDA”) for enclomiphene. Subsequently, we announced that the NDA was accepted by the FDA and the FDA assigned a Prescription Drug User Fee Act (“PDUFA”) goal date of November 30, 2015. In addition, the FDA has informed the Company that they plan to hold an advisory committee meeting during the review.
	Proellex®, our product candidate for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. On December 29, 2014, we announced that we have initiated two Phase 2B studies for low dose Proellex® in the treatment of uterine fibroids and are currently conducting a Phase 2 study in the treatment of endometriosis.
	Our product development pipeline, with dates as expected as of the date of this report, is summarized in the table below:
	Product Candidate (Indication)	Status	Next Expected Milestone(s)
	Enclomiphene
	Secondary Hypogonadism	NDA accepted and under review	PDUFA date of November 30, 2015
	Proellex®
	Uterine Fibroids	Phase 2	Complete first course of treatment in a Phase 2B study (oral delivery) (YE 2015)
			Complete first course of treatment in a Phase 2B study (vaginal delivery) (YE 2015)
	Endometriosis	Phase 2	Fully enroll Phase 2 study (oral delivery) (YE 2015)
	As of March 31, 2015, we had accumulated losses of $281.6 million, approximately $37.9 million in cash and cash equivalents, and accounts payable and accrued expenses of approximately $2.0 million, in the aggregate. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates into the second half of 2016. We continue to explore potential corporate partnering opportunities for assistance in the clinical development funding and commercialization of our products, as appropriate; however, there can be no assurance that an acceptable corporate partnering opportunity will be successfully completed or that our current liquidity will be sufficient to fund all of our product development needs.

Revision_of_Prior_Years_Financ

Revision of Prior Years' Financial Statements	3 Months Ended
	Mar. 31, 2015
Quantifying Prior Year Misstatements Corrected in Current Year Financial Statements [Abstract]
Revision Of Prior Yearsb Financial Statements	NOTE 2 — Revision of Prior Years’ Financial Statements
	While preparing its financial statements for the year ended December 31, 2014, the Company identified a prior period error related to the accounting for patent costs. As disclosed in its prior filings, historically the Company had capitalized patent related costs associated with its drug candidates, enclomiphene and Proellex®. However, the Company has now concluded that these costs should have been expensed as research and development costs since the related products were, at the time the costs were incurred, in the development phase and had not been approved by the FDA.  The Company concluded this error was not material individually or in the aggregate to any of the prior reporting periods, and therefore, no restatements of previously issued financial statements were necessary.  However, if the entire correction had been recorded in the fourth quarter of 2014, the cumulative impact would have been material to the fourth quarter of 2014, and would have impacted the comparability to prior periods.  As such, revisions for the prior periods are reflected in the financial statements herein. The quarter ended March 31, 2015 was not affected.
	At December 31, 2013, accumulated deficit and shareholders’ equity were reported as ($237,623) and $75,425, respectively, and were revised to ($240,529) and $72,519, respectively.
	The effects of the error correction on the consolidated statements of operations for the three month period ended March 31, 2014 are as follows (in thousands):
		Three months ended March 31, 2014
		As previously		Correction		As revised
		reported
	Research and development	$	7,325	$	244	$	7,569
	Total expenses		8,551		244		8,795
	Net loss		-8,549		-244		-8,793
	Loss per share – basic and diluted		-0.37		-0.01		-0.38
	The effects of the error correction on the consolidated statements of cash flows for the three month period ended March 31, 2014 are as follows (in thousands):
		Three months ended March 31, 2014
		As previously		Correction		As revised
		reported
	Net cash used in operating activities	$	-7,614	$	-285	$	-7,899
	Net cash used in investing activities		-285		285		0

Accrued_Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2015
Accrued Expenses [Abstract]
Accrued Expenses	NOTE 3 — Accrued Expenses
	Accrued expenses consist of the following (in thousands):
		March 31, 2015		December 31, 2014
	Research and development costs	$	654	$	284
	Personnel related costs		63		458
	Other		76		92
	Total	$	793	$	834

Loss_Per_Share

Loss Per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Loss Per Share	NOTE 4 — Loss Per Share
	Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed using the average share price for the period and applying the treasury stock method to potentially dilutive outstanding options. In all applicable periods, all potential common stock equivalents were anti-dilutive and, accordingly, were not included in the computation of diluted loss per share.
	The following table presents information necessary to calculate loss per share for the three month periods ended March 31, 2015 and 2014 (in thousands, except per share amounts):
		Three Months Ended March 31,
		2015		2014
	Net loss	$	-8,525	$	-8,793
	Average common shares outstanding		24,276		23,033
	Basic and diluted loss per share	$	-0.35	$	-0.38
	Potential common stock of 3,274,157 and 4,086,885 common shares underlying stock options and warrants for the periods ended March 31, 2015 and 2014, respectively, were excluded from the above calculation of diluted loss per share because they were anti-dilutive. Other potential common stock at March 31, 2015 includes Series A Warrants to purchase 39,595 shares of our common stock at an exercise price of $0.01 and Series B Warrants to purchase 429,704 shares of our common stock at an exercise price of $2.49 issued in our February 8, 2011 public offering. Other potential common stock at March 31, 2014 includes Series A Warrants to purchase 877,137 shares of our common stock at an exercise price of $0.01 and Series B Warrants to purchase 809,805 shares of our common stock at an exercise price of $2.49 issued in our February 8, 2011 public offering.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	NOTE 5 – Stock-Based Compensation
	During the three month period ended March 31, 2015, the Compensation Committee of the Company’s Board of Directors approved grants of options to purchase 369,000 shares of our common stock to certain employees and directors under the 2011 Equity Incentive Plan. All of these options vest in equal annual installments on the first three year anniversaries of the date of grant. Additionally, during the three month period ended March 31, 2015, 5,000 options either expired or were forfeited.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 6 — Commitments and Contingencies
	Therapeutic uses of our enclomiphene product candidate are covered in the United States by nine issued U.S. patents and nine pending patent applications. Foreign coverage of therapeutic uses of our enclomiphene product candidate includes 76 issued foreign patents and 99 foreign pending patent applications. The issued patents and pending applications relate to methods for treating certain conditions including the treatment of testosterone deficiency in men, the treatment of diabetes mellitus Type 2, the treatment of metabolic syndrome and conditions associated therewith, and the treatment of infertility in hypogonadal men. Enclomiphene (the trans-isomer of clomiphene) is purified from clomiphene citrate. A third party individual holds two issued patents related to the use of anti-estrogen such as clomiphene citrate and others for use in the treatment of androgen deficiency and disorders related thereto. We requested re-examination of one of these patents by the U.S. Patent and Trademark Office (“PTO”) based on prior art. The patent holder amended the claims in the re-examination proceedings, which led the PTO to determine that the amended claims were patentable in view of those publications under consideration and a re-examination certificate was issued. We subsequently filed a second request for re-examination by the PTO in light of a number of additional publications. The request was granted and all of the claims were finally rejected by the PTO in the re-examination. The patent holder appealed the rejections to the PTO Board of Patent Appeals and Interferences (the “PTO Board”) which ultimately reversed the rejections of several dependent claims in view of those publications under consideration. The patent holder filed a Notice of Appeal to the Federal Circuit on September 28, 2010 contesting the rejections maintained by the PTO Board. A decision was rendered by the Court of Appeals for the Federal Circuit on December 12, 2011, affirming the rejection of the appealed claims. The PTO issued an Ex Parte Reexamination Certificate on April 29, 2013, canceling the rejected claims and confirming the patentability of the remaining claims. Nevertheless, we believe that our development of enclomiphene does not infringe any of the remaining claims and that all of the remaining claims are invalid on various grounds including additional prior art publications. We also believe that the second of these two patents is invalid in view of published prior art not considered by the PTO. If necessary, we intend to vigorously defend any and all claims that may be brought by the holder of such patents in a court of competent jurisdiction in order to develop enclomiphene further. Adverse determinations in litigation proceedings could require us to seek licenses which may not be available on commercially reasonable terms, or at all, or subject us to significant liabilities, in which case we may not be able to successfully commercialize or out-license enclomiphene until such patents expire or are otherwise no longer in force.
	On July 19, 2013, we received a letter from Dr. Harry Fisch threatening to file a lawsuit against us and two of our executive officers (Joseph S. Podolski, President and Chief Executive Officer and Ron Wiehle, Executive Vice President), seeking addition of Dr. Harry Fisch as an inventor on three of our patents, U.S. Patent Nos. 7,173,064, 7,737,185 and 7,759,360, covering therapeutic uses of enclomiphene. We believe that these allegations are without merit and on August 2, 2013, we commenced a lawsuit against Dr. Fisch in the U.S. District Court for the Southern District of Texas seeking a declaratory judgment that he should not be added as inventor to any of these patents. On October 2, 2013, Dr. Fisch filed counterclaims to our complaint seeking correction of inventorship of the three patents at issue to name Dr. Fisch as a co-inventor of the applications leading to these patents. Dr. Fisch subsequently stipulated that he does not claim to be a co-inventor of U.S. Patent No. 7,173,064. The court granted summary judgment in favor of the Company on separate equitable and legal grounds, and entered judgment on December 23, 2014. Our request for attorney’s fees was denied. On February 9, 2015, Dr. Fisch filed a notice of appeal of the summary judgment rulings to the United States Court of Appeals for the Federal Circuit.

Organization_Operations_and_Li1

Organization, Operations and Liquidity (Tables)	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Product Development Pipeline	Our product development pipeline, with dates as expected as of the date of this report, is summarized in the table below:
	Product Candidate (Indication)	Status	Next Expected Milestone(s)
	Enclomiphene
	Secondary Hypogonadism	NDA accepted and under review	PDUFA date of November 30, 2015
	Proellex®
	Uterine Fibroids	Phase 2	Complete first course of treatment in a Phase 2B study (oral delivery) (YE 2015)
			Complete first course of treatment in a Phase 2B study (vaginal delivery) (YE 2015)
	Endometriosis	Phase 2	Fully enroll Phase 2 study (oral delivery) (YE 2015)

Revision_of_Prior_Years_Financ1

Revision of Prior Years' Financial Statements (Tables)	3 Months Ended
	Mar. 31, 2015
Quantifying Prior Year Misstatements Corrected in Current Year Financial Statements [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	The effects of the error correction on the consolidated statements of operations for the three month period ended March 31, 2014 are as follows (in thousands):
		Three months ended March 31, 2014
		As previously		Correction		As revised
		reported
	Research and development	$	7,325	$	244	$	7,569
	Total expenses		8,551		244		8,795
	Net loss		-8,549		-244		-8,793
	Loss per share – basic and diluted		-0.37		-0.01		-0.38
Schedule Of Error Corrections And Prior Period Adjustments Cash flows	The effects of the error correction on the consolidated statements of cash flows for the three month period ended March 31, 2014 are as follows (in thousands):
		Three months ended March 31, 2014
		As previously		Correction		As revised
		reported
	Net cash used in operating activities	$	-7,614	$	-285	$	-7,899
	Net cash used in investing activities		-285		285		0

Accrued_Expenses_Tables

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2015
Accrued Expenses [Abstract]
Accrued Expenses	Accrued expenses consist of the following (in thousands):
		March 31, 2015		December 31, 2014
	Research and development costs	$	654	$	284
	Personnel related costs		63		458
	Other		76		92
	Total	$	793	$	834

Loss_Per_Share_Tables

Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Calculation of Loss Per Share	The following table presents information necessary to calculate loss per share for the three month periods ended March 31, 2015 and 2014 (in thousands, except per share amounts):
		Three Months Ended March 31,
		2015		2014
	Net loss	$	-8,525	$	-8,793
	Average common shares outstanding		24,276		23,033
	Basic and diluted loss per share	$	-0.35	$	-0.38

Organization_Operations_and_Li2

Organization, Operations and Liquidity (Product Development Pipeline) (Details)	3 Months Ended
	Mar. 31, 2015
Enclomiphene [Member] | Secondary Hypogonadism [Member]
Product Information [Line Items]
Status	NDA accepted and under review
Next Expected Milestone(s)	PDUFA date of November 30, 2015
Proellex [Member] | Uterine Fibroids 1 [Member]
Product Information [Line Items]
Status	Phase 2
Next Expected Milestone(s)	Complete first course of treatment in a Phase 2B study (oral delivery) (YE 2015) Complete first course of treatment in a Phase 2B study (vaginal delivery) (YE 2015)
Proellex [Member] | Endometriosis [Member]
Product Information [Line Items]
Status	Phase 2
Next Expected Milestone(s)	Fully enroll Phase 2 study (oral delivery) (YE 2015)

Organization_Operations_and_Li3

Organization, Operations and Liquidity (Additional Information) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
Product Information [Line Items]
Deficit accumulated during the development stage	$281,600,000
Cash and cash equivalents	37,875,000	46,620,000	68,012,000	75,807,000
Accounts payable and accrued expenses	$2,000,000

Revision_of_Prior_Years_Financ2

Revision of Prior Years' Financial Statements (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Research and development	$7,321	$7,569
Total expenses	8,526	8,795
Net loss	-8,525	-8,793
Loss per share - basic and diluted	($0.35)	($0.38)
As Previously Reported [Member]
Research and development		7,325
Total expenses		8,551
Net loss		-8,549
Loss per share - basic and diluted		($0.37)
Correction [Member]
Research and development		244
Total expenses		244
Net loss		($244)
Loss per share - basic and diluted		($0.01)

Revision_of_Prior_Years_Financ3

Revision of Prior Years' Financial Statements (Details 1) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net cash used in operating activities	($8,847)	($7,899)
Net cash used in investing activities	0	0
As Previously Reported [Member]
Net cash used in operating activities		-7,614
Net cash used in investing activities		-285
Correction [Member]
Net cash used in operating activities		-285
Net cash used in investing activities		$285

Revision_of_Prior_Years_Financ4

Revision of Prior Years' Financial Statements (Additional information) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Quantifying Misstatement in Current Year Financial Statements [Line Items]
Shareholdersb Equity	$36,514	$44,017	$64,750	$72,519
Retained Earnings (Accumulated Deficit)	-281,589	-273,064		-240,529
Scenario, Previously Reported [Member]
Quantifying Misstatement in Current Year Financial Statements [Line Items]
Shareholdersb Equity				75,425
Retained Earnings (Accumulated Deficit)				($237,623)

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Schedule Of Accrued Liabilities [Line Items]
Research and development costs	$654	$284
Personnel related costs	63	458
Other	76	92
Total	$793	$834

Loss_Per_Share_Calculation_of_

Loss Per Share (Calculation of Loss Per Share) (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net loss	($8,525)	($8,793)
Average common shares outstanding	24,276	23,033
Basic and diluted loss per share	($0.35)	($0.38)

Loss_Per_Share_Additional_Info

Loss Per Share (Additional Information) (Details) (USD $)	Mar. 31, 2015	Mar. 31, 2014
Maximum [Member]
Earnings Per Share Disclosure [Line Items]
Anti-dilutive shares of common stock excluded from computation of earning per share	3,274,157	4,086,885
Series A Warrants [Member]
Earnings Per Share Disclosure [Line Items]
Anti-dilutive shares of common stock excluded from computation of earning per share	39,595	877,137
Warrants, exercise price per share	0.01	0.01
Series B Warrants [Member]
Earnings Per Share Disclosure [Line Items]
Anti-dilutive shares of common stock excluded from computation of earning per share	429,704	809,805
Warrants, exercise price per share	2.49	2.49

StockBased_Compensation_Additi

Stock-Based Compensation (Additional Information) (Details) (2011 Equity Incentive Plan Member)	3 Months Ended
	Mar. 31, 2015
2011 Equity Incentive Plan Member
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	369,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	5,000

Commitments_and_Contingencies_

Commitments and Contingencies (Additional Information) (Details)	3 Months Ended
	Mar. 31, 2015
Domestic [Member]
Commitments and Contingencies [Line Items]
Number of patents	9
Number of pending patent applications	9
Foreign [Member]
Commitments and Contingencies [Line Items]
Number of patents	76
Number of pending patent applications	99
Third Party [Member]
Commitments and Contingencies [Line Items]
Number of patents	2